[Federal Register Volume 68, Number 116 (Tuesday, June 17, 2003)]
[Notices]
[Pages 35894-35895]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-15214]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-03-78]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call the CDC Reports 
Clearance Officer on (404)498-1210.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology. Send comments to Seleda Perryman, CDC 
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24, 
Atlanta, GA 30333. Written comments should be received within 60 days 
of this notice.

Proposed Project

    Delayed symptoms associated with the convalescent period of a 
dengue infection.--New--National Center for Infectious Diseases 
(NCID)--Centers for Disease Control and Prevention (CDC). Dengue is a 
vector-borne febrile disease of the tropics transmitted most often by 
the mosquito Aedes aegypti. Symptoms of the acute disease include 
fever, headache, rash, retro-orbital pain, myalgias, arthralgias, 
vomiting, abdominal pain and hemorrhagic manifestations.
    Many symptoms are mentioned in the medical literature as associated 
with the convalescent period (three-eight weeks) after dengue 
infection, including depression, dementia, loss of sensation, paralysis 
of lower and upper extremities and larynx, epilepsy, tremors, manic 
psychosis, amnesia, loss of visual acuity, hair loss, and peeling of 
skin. No epidemiologic study has been conducted to define the timing, 
frequency, and risk factors for these symptoms. The objective of this 
study is to examine the incidence and characteristics of mental health 
disorders and other delayed complications associated with dengue 
infection and convalescence. The study will be conducted in Puerto 
Rico, where dengue is endemic and causes severe sporadic epidemics. 
Laboratory positive confirmed cases of dengue, laboratory

[[Page 35895]]

negative suspected dengue cases, and neighborhood controls will be 
prospectively enrolled in the study. Person-to-person interviews with 
adults (age 18 years or greater), will be conducted and information 
will be collected regarding symptoms experienced during the 
convalescent phase of the infection. There are no costs to respondents.

----------------------------------------------------------------------------------------------------------------
                                                                                      Average
                                                     Number of       Number of      burden per     Total burden
                   Respondents                      respondents    responses per   response (in      (in hrs.)
                                                                    respondent         hrs.)
----------------------------------------------------------------------------------------------------------------
Laboratory positive confirmed dengue............             200               2           60/60             400
Dengue negative control.........................             200               2           60/60             400
Neighborhood control............................             200               2           60/60             400
Total...........................................  ..............  ..............  ..............            1200
----------------------------------------------------------------------------------------------------------------


    Dated: June 10, 2003.
Thomas A. Bartenfeld,
Acting Associate Director for Policy, Planning and Evaluation, Centers 
for Disease Control. and Prevention.
[FR Doc. 03-15214 Filed 6-16-03; 8:45 am]
BILLING CODE 4163-18-P